Glenmark Pharmaceuticals | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Conferences Trial results

4 June 2025

ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers

Meanwhile, Ichnos Glenmark takes a different bispecific multiple myeloma approach.

Subscribe to Glenmark Pharmaceuticals